Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells

Shasha Cheng; Guan-Jun Yang; Wanhe Wang; Dik-Lung Ma; Chung-Hang Leung

doi:10.1016/j.gendis.2021.06.005

您当前的位置：

首页 >

文章列表页 >

Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells

Full-length article | 更新时间：2022-11-09

- Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells
- Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells
- Genes & Diseases 2022年9卷第6期
- 作者机构：
  
  1. State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa,Macao SAR,PR China
  2. Department of Chemistry, Hong Kong Baptist University, Kowloon Tong,Hong Kong SAR,PR China
  3. Institute of Medical Research, Northwestern Polytechnical University,Shaanxi,Xi'an,PR China,710072
  4. Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau,Macao SAR,PR China
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2021.06.005
  中图分类号：
- 纸质出版日期：2022，
  
  网络出版日期：2022-11-1，
扫描看全文
Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells[J]. Genes & Diseases, 2022,9(6).

Shasha Cheng, Guan-Jun Yang, Wanhe Wang, et al. Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells[J]. Genes & Diseases, 2022,9(6).
Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells[J]. Genes & Diseases, 2022,9(6). DOI： 10.1016/j.gendis.2021.06.005.

Shasha Cheng, Guan-Jun Yang, Wanhe Wang, et al. Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells[J]. Genes & Diseases, 2022,9(6). DOI： 10.1016/j.gendis.2021.06.005.

摘要

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive and metastasizing cancer that has the worst prognosis out of all breast cancer subtypes. The epithelial–mesenchymal transition (EMT) and cancer stem cells (CSCs) have been proposed as important mechanisms underlying TNBC metastasis. CDK9 is highly expressed in breast cancer

including TNBC

where it promotes EMT and induces cancer cell stemness. In this study

we have identified a tetrahydroisoquinoline derivative (compound 1) as a potent and selective CDK9-cyclin T1 inhibitor via virtual screening. Interestingly

by targeting the ATP binding site

compound 1 not only inhibited CDK9 activity but also disrupted the CDK9-cyclin T1 protein–protein interaction (PPI). Mechanistically

compound 1 reversed EMT and reduced the ratio of CSCs by blocking the CDK9-cyclin T1 interaction

leading to reduced TNBC cell proliferation and migration. To date

compound 1 is the first reported tetrahydroisoquinoline-based CDK9-cyclin T1 ATP-competitive inhibitor that also interferes with the interaction between CDK9 and cyclin T1. Compound 1 may serve as a promising scaffold for developing more selective and potent anti-TNBC agents. Our work also provides insight into the role of the CDK9-cyclin T1 PPI on EMT and CSCs and highlights the feasibility and significance of targeting CDK9 for the treatment of TNBC.

关键词

Keywords

Cancer stem cellsCDK9-cyclin T1Epithelial mesenchymal transitionProtein–protein interaction (PPI)Triple-negative breast cancer (TNBC)

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities

Tumor microenvironment of cancer stem cells: Perspectives on cancer stem cell targeting

Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance